Caspase: Pharmacological manipulation of cell death

Journal of Clinical Investigation

Volumn 115, Issue 10, 2005, Pages 2665-2672

  Lavrik, Inna N ^a   Golks, Alexander ^a   Krammer, Peter H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; APOPTOSOME; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; CASPASE 10; CASPASE 11; CASPASE 12; CASPASE 13; CASPASE 14; CASPASE 2; CASPASE 3; CASPASE 4; CASPASE 5; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYSTEINE PROTEINASE; DEATH RECEPTOR; DNA; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; MX 116407; MX 128504; MX 2167; MX 90745; PRALNACASAN; PROTEIN P43; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; PROTEINASE INHIBITOR;

ALPHA HELIX; APOPTOSIS; BETA SHEET; CAENORHABDITIS ELEGANS; CELL DEATH; DRUG DESIGN; ENZYME ACTIVATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HUMAN; NONHUMAN; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; ANIMAL; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOPTOSIS; CASPASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PROTEASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 26444560960     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI26252     Document Type: Review

References (89)

1. Krammer, P.H. 2000. CD95's deadly mission in the immune system. Nature. 407:789-795.
2. Danial, N.N., and Korsmeyer, S.J. 2004. Cell death: ctitical control points. Cell 116:205-219.
3. Ashkenazi, A., and Dixit, V.M. 1998. Death receptors: signaling and modulation. Science. 281:1305-1308.
4. Krammer, P.H. 1998. The CD95 (APO-1/Fas)/CD95L system [review]. Toxicol. Lett. 102-103:131-137.
5. Thornberry, N.A., and Lazebnik, Y. 1998. Caspases: enemies within. Science. 281:1312-1316.
6. Cohen, G.M. 1997. Caspases: the executioners of apoptosis. Biochem. J. 326:1-16.
7. Nicholson, D.W. 1999. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6:1028-1042.
8. Alnemri, E.S., et al. 1996. Human ICE/CED-3 protease nomenclature [letter]. Cell. 87:171.
9. Weber, C.H., and Vincenz, C. 2001. The death domain superfamily: a tale of two interfaces [review]? Trends Biochem. Sci. 26:475-481.
10. Martinon, F., Hofmann, K., and Tschopp, J. 2001. The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr. Biol. 11:R118-R120.
11. Fesik, S.W. 2000. Insights into programmed cell death through structural biology. Cell. 103:273-282.
12. Hofmann, K. 1999. The modular nature of apoptotic signaling proteins. Cell. Mol. Life Sci. 55:1113-1128.
13. Eberstadt, M., et al. 1998. NMR structure and mutagenesis of the FADD (Mort1) death-effector domain. Nature. 392:941-945.
14. Muzio, M., et al. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:817-827.
15. Sprick, M., et al. 2002. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 21:4520-4530.
16. Fuentes-Prior, P., and Salvesen, G.S. 2004. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem. J. 384:201-232.
17. Lamkanfi, M., et al. 2005. A novel caspase-2 complex containing TRAF2 and RIP1. J. Biol. Chem. 280:6923-6932.
18. Walker, N.P., et al. 1994. Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: a (p20/p10)2 homodimer. Cell. 78:343-352.
19. Wilson, K.P., et al. 1994. Structure and mechanism of interleukin-1 beta converting enzyme. Nature. 370:270-275.
20. Schweizer, A., Briand, C., and Grutter, M.G. 2003. Crystal structure of caspase-2, apical initiator of the intrinsic apoptotic pathway. J. Biol. Chem. 278:42441-42447.
21. Rotonda, J., et al. 1996. The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis. Nat. Struct. Biol. 3:619-625.
22. Mittl, P.R., et al. 1997. Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-Asp-Val-Ala-Asp fluoromethyl ketone. J. Biol. Chem. 272:6539-6547.
23. Riedl, S.J., et al. 2001. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 104:791-800.
24. Wei, Y., et al. 2000. The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity. Chem. Biol. 7:423-432.
25. Chai, J., et al. 2001. Structural basis of caspase-7 inhibition by XIAP. Cell. 104:769-780.
26. Huang, Y., et al. 2001. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell. 104:781-790.
27. Blanchard, H., et al. 1999. The three-dimensional structure of caspase-8: an initiator enzyme in apoptosis. Structure Fold. Des. 7:1125-1133.
28. Renatus, M., Stennicke, H.R., Scott, F.L., Liddington, R.C., and Salvesen, G.S. 2001. Dimer formation drives the activation of the cell death protease caspase 9. Proc. Natl. Acad. Sci. U. S. A. 98:14250-14255.
29. Eichinger, A., et al. 1999. Crystal structure of gingi-pain R: an Arg-specific bacterial cysteine proteinase with a caspase-like fold. EMBO J. 18:5453-5462.
30. Thornberry, N.A., et al. 1997. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272:17907-17911.
31. Boatright, K.M., et al. 2003. A unified model for apical caspase activation. Mol. Cell. 11:529-541.
32. Shi, Y. 2002. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell. 9:459-470.
33. Graybill, T.L., Dolle, R.E., Helaszek, C.T., Miller, R.E., and Ator, M.A. 1994. Preparation and evaluation of peptidic aspartyl hemiacetals as reversible inhibitors of interleukin-1 beta converting enzyme (ICE). Int. Pept. Protein Res. 44:173-182.
34. Estrov, Z., et al. 1995. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood. 86:4594-4602.
35. Thornberry, N.A., et al. 1992. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 356:768-774.
36. Chang, D.W., et al. 2002. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 21:3704-3714.
37. Tartaglia, L.A., Ayres, T.M., Wong, G.H., and Goeddel, D.V. 1993. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 74:845-853.
38. Kischkel, F.C., et al. 1995. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14:5579-5588.
39. Scaffidi, C., Medema, J.P., Krammer, P.H., and Peter, M.E. 1997. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 272:26953-26958.
40. Scaffidi, C, et al. 1999. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 274:22532-22538.
41. Scaffidi, C., Krammer, P.H., and Peter, M.E. 1999. Isolation and analysis of components of CD95 (APO-1/Fas) death-inducing signaling complex. Methods. 17:287-291.
42. Scaffidi, C., Kischkel, F.C., Krammer, P.H., and Peter, M.E. 1999. Analysis of the CD95 (APO-1/Fas) death-inducing signaling complex (DISC) by high resolution two-dimensional gel electrophoresis. Methods Enzymol. 322:363-373.
43. Peter, M.E., and Krammer, P.H. 2003. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26-35.
44. Golks, A., Brenner, D., Fricsch, C., Krammer, P.H., and Lavrik, I.N. 2005. C-FLIPR: a new regulator of death receptor-induced apoptosis. J. Biol. Chem. 280:14507-14513.
45. Chang, D.W., Xing, Z., Capacio, V.L., Peter, M.E., and Yang, X. 2003. Interdimer processing mechanism of procaspase-8 activation. EMBO J. 22:4132-4142.
46. Muzio, M., Stockwell, B.R., Stennicke, H.R., Salvesen, G.S., and Dixit, V.M. 1998. An induced proximity model for caspase-8 activation. J. Biol. Chem. 273:2926-2930.
47. Martin, D.A., Siegel, R.M., Zheng, L., and Lenardo, M.J. 1998. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. J. Biol. Chem. 273:4345-4349.
48. Lavrik, I., et al. 2003. The active caspase-8 heterotetramer is formed at the CD95 DISC. Cell Death Differ. 10:144-145.
49. Kischkel, F.C., et al. 2001. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276:46639-46646.
50. Acehan, D., et al. 2002. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol. Cell. 9:423-432.
51. Hengartner, M.O. 1999. Programmed cell death in the nematode C. elegans [review]. Recent Prog. Harm. Res. 54:213-222; discussion 222-214.
52. Chinnaiyan, A.M. 1999. The apoptosome: heart and soul of the cell death machine. Neoplasia. 1:5-15.
53. Jiang, X., and Wang, X. 2000. Cytochrome c promotes caspase-9 activation by inducing nucleotide bindingto Apaf-1. J. Biol. Chem. 275:31199-31203.
54. Martinon, F., and Tschopp, J. 2004. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell. 117:561-574.
55. Scaffidi, C., et al. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1675-1687.
56. Korsmeyer, S.J., et al. 2000. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 7:1166-1173.
57. Robertson, J.D., Enoksson, M., Suomela, M., Zhivotovsky, B., and Orrenius, S. 2002. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol. Chem. 277:29803-29809.
58. Lassus, P., Opitz-Araya, X., and Lazebnik, Y. 2002. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science. 297:1352-1354.
59. Thome, M., et al. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 386:517-521.
60. Scaffidi, C., Schmitz, I., Krammer, P.H., and Peter, M.E. 1999. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 274:1541-1548.
61. Golks, A., Brenner, D., Fritsch, C., Krammer, P.H., and Lavrik, I.N. 2005. C-FLIPR: a new regulator of death receptor-induced apoptosis. J. Biol. Chem. 280:14507-14513.
62. Krueger, A., Schmitz, I., Baumann, S., Krammer, P.H., and Kirchhoff, S. 2001. Cellular flice-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the cd95 death-inducing signaling complex. J. Biol. Chem. 276:20633-20640.
63. Micheau, O., et al. 2002. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex J. Biol. Chem. 277:45162-45171.
64. Deveraux, Q.L., and Reed, J.C. 1999. IAP family proteins: suppressors of apoptosis. Genes Dev. 13:239-252.
65. Ashhab, Y., Alian, A., Polliack, A., Panec, A., and Ben Yehuda, D. 2001. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 495:56-60.
66. Vucic, D., Stennicke, H.R., Pisabarro, M.T., Salvesen, G.S., and Dixit, V.M. 2000. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 10:1359-1366.
67. Srinivasula, S.M., et al. 2001. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 410:112-116.
68. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. 2000. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33-42.
69. Ekert, P.G., Silke, J., Hawkins, C.J., Verhagen, A.M., and Vaux, D.L. 2001. DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9. J. Cell Biol. 152:483-490.
70. Suzuki, Y., et al. 2001. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell. 8:613-621.
71. Miller, L.K. 1999. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 9:323-328.
72. Xu, G., et al. 2001. Covalent inhibition revealed by the crystal structure of the caspase-8/p35 complex. Nature. 410:494-497.
73. Renatus, M., et al. 2000. Crystal structure of the apoptotic suppressor CrmA in its cleaved form. Structure Fold. Des. 8:789-797.
74. Endres, M., et al. 1998. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J. Cereb. Blood Flow Metab. 18:238-247.
75. Wiessner, C., Sauer, D., Alaimo, D., and Allegrini, P.R. 2000. Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo. Cell. Mol. Biol (Noisy-le-grand). 46:53-62.
76. Rabuffetti, M., et al. 2000. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J. Neurosci. 20:4398-4404.
77. Hoglen, N.C., et al. 2004. Characterization of IDN-6556 (3-{2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-{2,3,5, 6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J. Pharmacol. Exp. Ther. 309:634-640.
78. Leung-Toung, R., Li, W., Tam, T.F., and Karimian, K. 2002. Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem. 9:979-1002.
79. Stockwell, B.R. 2000. Chemical genetics: ligand-based discovery of gene function. Nat. Rev. Genet. 1:116-125.
80. Jiang, X., et al. 2003. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science. 299:223-226.
81. Nguyen, J.T., and Wells, J.A. 2003. Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100:7533-7538.
82. Maxim Pharmaceuticals. 2004. Annual Report 2004.
83. Jia, L.T., et al. 2003. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res. 63:3257-3262.
84. Xu, Y.M., et al. 2004. A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J. Immunol. 173:61-67.
85. Schimmer, A.D., et al. 2004. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 5:25-35.
86. Glover, C.J., et al. 2003. A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay. Anal. Biochem. 320:157-169.
87. Tamm, I., et al. 2003. Peptides targeting caspase inhibitors. J. Biol. Chem. 278:14401-14405.
88. Wu, T.Y., Wagner, K.W., Bursulaya, B., Schultz, P.G., and Deveraux, Q.L. 2003. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem. Biol. 10:759-767.
89. Reed, J. 2002. Apoptosis-based therapies. Nat. Rev. Drug Discov. 1:111-121.